Educational tool onlyOutside MHRA medical device scopeGDPR compliantAnonymous, no name collected

Tool type

Symptom signal check

Not a medical device

Regulatory scope

Outside MHRA Class I

Educational framing only

This page documents the methodology behind SUMM's symptom signal check. It explains the 15 questions, the scoring logic, the clinical frameworks used, and the regulatory position.

The 15 questions and how they are scored

Each question targets a specific symptom dimension. The evidence basis column explains why that question exists and which clinical framework informs the scoring weight.

#QuestionScreens forEvidence basis
1How old are you?Age-based riskSTRAW+10 staging (perimenopause typically 38–55, thyroid risk increases 40+)
2Energy levelsFatigue typeBurnout: improves with rest (Maslach 2016). Hormonal/thyroid: persistent regardless (EMAS 2024, NICE NG23)
3SleepDisruption typePhysical waking = vasomotor = perimenopause (NICE NG23). Racing thoughts = burnout. Excessive unrefreshed = hypothyroid (EMAS 2024)
4TemperatureRegulationFeeling cold = hypothyroid hallmark (EMAS 2024). Hot flushes = perimenopause. Critical differentiator.
5WeightChanges patternAbdominal gain = perimenopause (STRAW+10). Whole body puffy = hypothyroid. Loss while eating = hyperthyroid (EMAS 2024)
6MoodType of changeSituational anxiety = burnout (Maslach 2016). Unprovoked anxiety/rage = perimenopause (MRS). Jittery = hyperthyroid (EMAS 2024)
7CognitionFog typeWorkload-tied = burnout. Consistent = perimenopause or hypothyroid. Processing slowness = hypothyroid (EMAS 2024, Maki 2024)
8PeriodsCycle changesHeavy = early perimenopause (STRAW+10). Light/missed = later perimenopause or thyroid. Both conditions affect cycle (EMAS 2024)
9Hair and skinChangesHair + dry skin + cold = hypothyroid triad (EMAS 2024, ATA guidelines). Perimenopause causes milder changes.
10PalpitationsTypeHot flush-associated = perimenopause vasomotor (NICE NG23). Frequent + tremor = hyperthyroid (EMAS 2024). Stress-linked = burnout.
11Appetite/weightCombinedEating more, losing weight = hyperthyroid. No appetite, gaining = hypothyroid. Sugar cravings = perimenopause (STRAW+10)
12Stress relationshipKEY DIFFERENTIATORImproves on holiday = burnout (Maslach 2016). Does not improve = hormonal/thyroid. Cyclical = perimenopause (STRAW+10)
13Physical symptomsSpecific markersVaginal dryness = perimenopause (Monash/Lancet 2025). Constipation = hypothyroid. Throat = thyroid investigation.
14NutritionDeficiency screenIron, D, B12 deficiency mimic burnout and perimenopause. NICE differential diagnosis guidance.
15Blood testsHistoryTSH not checked = thyroid signal weighted higher. Normal + ongoing symptoms = diagnose on symptoms over 45 (NICE NG23)

How results are calculated

Each answer contributes weighted points to one or more of four scores: Perimenopause (P), Thyroid (T), Burnout (B), and Nutritional (N). The final result type is determined by the combination of scores that cross threshold.

Result typeTrigger conditionMeaning
HIGH_PERIP ≥ 7, T < 5Strong perimenopause signal. Recommend GP conversation about HRT eligibility and symptom management.
HIGH_THYROIDT ≥ 7, P < 5Strong thyroid signal. Recommend TSH, FT4, and thyroid antibody testing.
HIGH_BURNOUTB ≥ 7, P < 4, T < 4Strong burnout signal. Symptoms likely stress-driven. Recommend lifestyle and occupational health review.
PERI_THYROIDP ≥ 5 AND T ≥ 5Overlapping perimenopause and thyroid signals. Both pathways should be investigated.
MIXED_ALLAll scores 3–6No single dominant signal. Multiple contributing factors likely. Broad-spectrum investigation recommended.
NUTRITIONALN ≥ 5, others < 4Nutritional deficiency signal dominant. Screen iron, vitamin D, B12, folate before hormonal investigation.

Clinical frameworks

Symptom measurement

Menopause Rating Scale (MRS)

Heinemann K, et al. The Menopause Rating Scale (MRS): a methodological review. Health Qual Life Outcomes. 2004;2:45.

doi:10.1186/1477-7525-2-45

Staging framework

STRAW+10 Staging Criteria

Harlow SD, et al. Executive summary of the Stages of Reproductive Aging Workshop +10. Menopause. 2012;19(4):387-395.

doi:10.1097/gme.0b013e31824d8f40

Differential framework

EMAS 2024 Thyroid-Menopause Position

Mintziori G, et al. EMAS position statement: Thyroid disease and menopause. Maturitas. 2024.

doi:10.1016/j.maturitas.2024.00086

Burnout differentiation

Maslach & Leiter 2016 + NICE NG23

Maslach C & Leiter MP. Understanding the burnout experience. World Psychiatry. 2016;15(2):103-111. NICE NG23 Menopause: diagnosis and management. 2015 (updated 2019).

What the tool does and does not do

Does not

  • Diagnose any medical condition
  • Match symptoms to named conditions
  • Indicate the seriousness of symptoms
  • Provide triage recommendations
  • Output a probability of diagnosis
  • Recommend specific treatments
  • Store or transmit personal health data

Does

  • Collect self-reported symptom data entered by the user
  • Organise responses into four signal areas
  • Present general health information relevant to midlife women
  • Generate a structured summary for GP conversations
  • Signpost to relevant clinical tests and professional support

MHRA regulatory position

Under MHRA guidance on Software as a Medical Device (SaMD, 2023), software that collects and organises self-reported data without performing diagnostic matching, clinical decision support, or triage signposting falls outside the definition of a medical device. SUMM has been designed specifically to remain within this boundary. The tool does not interpret, weight, or match symptoms against diagnostic criteria in a way that constitutes clinical decision support. It organises user input into thematic areas for the user's own reference.

MHRA guidance: Medical devices — software applications (apps)

The information on this page is provided for transparency and does not constitute a formal regulatory submission. SUMM is a self-reported symptom signal check. It does not diagnose, treat, or assess any medical condition. All citations link to publicly available peer-reviewed sources. Last reviewed April 2026.